MCP-4 (CCL8)
CCL8proteinMonocyte-recruiting chemokine amplifying acute inflammatory response in STEMI plaque rupture.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleMonocyte and eosinophil chemokine; STEMI inflammation marker reflects acute plaque inflammation.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000108700
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I26
C — confounder / Type-II57
A — assay feasibility68
E — evidence strength21
T1DI (composite)5
Specificity differential (R−C)-30.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation.Scientific reports · 2022 · PMID 35552514 · doi